PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 30, 2026Journal of Clinical Oncology0 citations

Association of acute kidney injury with in-hospital mortality and resource utilization among U.S. solid tumor hospitalizations: A National Inpatient Sample analysis, 2018–2022.

View Full Paper
CTCarter TaysomRSRamaditya SrinivasmurthyRHRiccesha Hattin

Key Points

  • This research aims to evaluate the impact of acute kidney injury on in-hospital mortality and resource use in cancer patients with solid tumors.
  • Retrospective cohort study using National Inpatient Sample data from 2018 to 2022
  • Identified adult hospitalizations with solid tumor malignancy using ICD-10-CM codes
  • Analyses adjusted for complex survey design to ensure national representativeness
  • 13.49% of the 4,298,089 identified hospitalizations had AKI.
  • In-hospital mortality was significantly higher with AKI (12.30%) compared to without (2.78%), a difference of 9.52%.
  • Mean length of stay was longer for AKI patients (9.71 days vs. 5.58 days), and total charges were higher ($138,994 vs. $93,009).

Abstract

e23163 Background: Acute kidney injury (AKI) is a common and clinically significant complication among patients hospitalized with cancer. Despite its known impact on outcomes, contemporary national data evaluating the association between AKI, inpatient mortality, and healthcare resource utilization among hospitalizations primarily for solid tumors remain limited. This study aimed to assess the relationship between AKI and in-hospital mortality, length of stay, and resource utilization in cancer-related hospitalizations at a national level. Methods: A retrospective, hospitalization-level cohort study was conducted using the Healthcare Cost and Utilization Project National Inpatient Sample (NIS) from 2018 to 2022. Adult hospitalizations with a principal diagnosis of solid tumor malignancy were identified using ICD-10-CM diagnosis codes, excluding hematologic malignancies. AKI was defined by the presence of ICD-10-CM code N17* in any diagnosis position. Analyses accounted for the complex NIS survey design using discharge-level weights, hospital clustering, and stratification variables to generate nationally representative estimates. Primary outcomes included in-hospital mortality, length of stay (LOS), and total hospitalization charges. Results: An estimated 4, 298, 089 hospitalizations with a principal diagnosis of solid tumor malignancy were identified (95% CI 4, 197, 740–4, 398, 438), of which 13. 49% (95% CI 13. 35%–13. 62%) were complicated by AKI. In-hospital mortality was higher among hospitalizations with AKI compared with those without AKI (12. 30% 95% CI 12. 08%–12. 53% vs 2. 78% 95% CI 2. 65%–2. 91%; absolute difference 9. 52%). Hospitalizations complicated by AKI had longer mean LOS (9. 71 days 95% CI 9. 63–9. 79) than those without AKI (5. 58 days 95% CI 5. 54–5. 61; difference 4. 13 days). Mean total hospitalization charges were also higher in the AKI group (138, 994 95% CI 136, 177–141, 811) compared with hospitalizations without AKI (93, 009 95% CI 91, 489–94, 529; difference 45, 985). Conclusions: In a nationally representative sample of U. S. hospitalizations primarily for solid tumors, AKI was common and was associated with higher in-hospital mortality, longer hospitalization, and substantially greater resource utilization. These findings underscore the significant inpatient burden associated with AKI in oncology populations and support the importance of hospitalization-level risk stratification and system-based strategies aimed at mitigating kidney-related complications during cancer care.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Taysom et al. (2026) studied this question.

synapsesocial.com/papers/6a1a80c00307b78509432bd0https://doi.org/10.1200/jco.2026.44.16_suppl.e23163
Ask AI
Helpful
Bookmark
Share
View Full Paper